Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy

  • Castillo, Gloria
  • Martinez Perez, Paola
  • Gonzalez Medina, Alberto
  • Vila-Casadesús, Maria
  • Gómez-Rey, Marina
  • Fabregat Franco, Carles
  • TIAN, TIAN
  • Castet, Florian
  • Matito, Judit
  • Miquel Aymar, Josep Maria
  • Nuciforo, Paolo
  • Perez-Lopez, Raquel
  • Vivancos, Ana
  • SIERRA, ALEXANDRE
  • Macarulla, Teresa
Liquid biopsy; Cholangiocarcinoma; Targeted therapy, Biopsia líquida; Colangiocarcinoma; Terapia dirigida, Biòpsia líquida; Colangiocarcinoma; Teràpia dirigida, Purpose: FGFR2 fusions occur in 10% to 15% of patients with intrahepatic cholangiocarcinoma (iCCA), potentially benefiting from FGFR inhibitors (FGFRi). We aimed to assess the feasibility of detecting FGFR2 fusions in plasma and explore plasma biomarkers for managing FGFRi treatment. Experimental design: We conducted a retrospective study in 18 patients with iCCA and known FGFR2 fusions previously identified in tissue samples from prior FGFRi treatment. Both tissue and synchronous plasma samples were analyzed using a custom hybrid capture gene panel with next-generation sequencing (VHIO-iCCA panel) and validated against commercial vendor results. Longitudinal plasma analysis during FGFRi was performed. Subsequently, we explored the correlation between plasma biomarkers, liver enzymes, tumor volume, and clinical outcomes. Results: Sixteen patients (88.9%) were positive for FGFR2 fusion events in plasma. Remarkably, the analysis of plasma suggests that lower levels of ctDNA are linked to clinical benefits from targeted therapy and result in improved progression-free survival and overall survival. Higher concentrations of cell-free DNA before FGFRi treatment were linked to worse overall survival, correlating with impaired liver function and indicating compromised cell-free DNA removal by the liver. Additionally, increased ctDNA or the emergence of resistance mutations allowed earlier detection of disease progression compared with standard radiologic imaging methods. Conclusions: VHIO-iCCA demonstrated accurate detection of FGFR2 fusions in plasma. The integration of information from various plasma biomarkers holds the potential to predict clinical outcomes and identify treatment failure prior to radiologic progression, offering valuable guidance for the clinical management of patients with iCCA., This study was supported by Incyte Corporation (Wilmington, DE; project title: “Identification of FGFR2 alterations by liquid biopsy and correlation with tissue biopsies in patients with cholangiocarcinoma”), the Asociación Española contra el Cáncer (AECC, Spain), and the FERO Foundation. A. Gonzalez-Medina is supported by the grant FJC2019-039770-I funded by Agencia Estatal de Investigación of Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033, Spain). R. Pérez-López. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Prostate Cancer Foundation (18YOUN19), and the Asociación Española Contra el Cáncer (AECC; PRYCO211023SERR, funding CM). A. Vivancos is supported by the Instituto de Salud Carlos III-investigación en Salud (PI20/01112). Some pictures were created with BioRender.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy

  • Castillo, Gloria
  • Martinez Perez, Paola
  • Gonzalez Medina, Alberto
  • Vila-Casadesús, Maria
  • Gómez-Rey, Marina
  • Fabregat Franco, Carles
  • TIAN, TIAN
  • Castet, Florian
  • Matito, Judit
  • Miquel Aymar, Josep Maria
  • Nuciforo, Paolo
  • Perez-Lopez, Raquel
  • Vivancos, Ana
  • SIERRA, ALEXANDRE
  • Macarulla, Teresa
Liquid biopsy; Cholangiocarcinoma; Targeted therapy, Biopsia líquida; Colangiocarcinoma; Terapia dirigida, Biòpsia líquida; Colangiocarcinoma; Teràpia dirigida, Purpose: FGFR2 fusions occur in 10% to 15% of patients with intrahepatic cholangiocarcinoma (iCCA), potentially benefiting from FGFR inhibitors (FGFRi). We aimed to assess the feasibility of detecting FGFR2 fusions in plasma and explore plasma biomarkers for managing FGFRi treatment. Experimental design: We conducted a retrospective study in 18 patients with iCCA and known FGFR2 fusions previously identified in tissue samples from prior FGFRi treatment. Both tissue and synchronous plasma samples were analyzed using a custom hybrid capture gene panel with next-generation sequencing (VHIO-iCCA panel) and validated against commercial vendor results. Longitudinal plasma analysis during FGFRi was performed. Subsequently, we explored the correlation between plasma biomarkers, liver enzymes, tumor volume, and clinical outcomes. Results: Sixteen patients (88.9%) were positive for FGFR2 fusion events in plasma. Remarkably, the analysis of plasma suggests that lower levels of ctDNA are linked to clinical benefits from targeted therapy and result in improved progression-free survival and overall survival. Higher concentrations of cell-free DNA before FGFRi treatment were linked to worse overall survival, correlating with impaired liver function and indicating compromised cell-free DNA removal by the liver. Additionally, increased ctDNA or the emergence of resistance mutations allowed earlier detection of disease progression compared with standard radiologic imaging methods. Conclusions: VHIO-iCCA demonstrated accurate detection of FGFR2 fusions in plasma. The integration of information from various plasma biomarkers holds the potential to predict clinical outcomes and identify treatment failure prior to radiologic progression, offering valuable guidance for the clinical management of patients with iCCA., This study was supported by Incyte Corporation (Wilmington, DE; project title: “Identification of FGFR2 alterations by liquid biopsy and correlation with tissue biopsies in patients with cholangiocarcinoma”), the Asociación Española contra el Cáncer (AECC, Spain), and the FERO Foundation. A. Gonzalez-Medina is supported by the grant FJC2019-039770-I funded by Agencia Estatal de Investigación of Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033, Spain). R. Pérez-López. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Prostate Cancer Foundation (18YOUN19), and the Asociación Española Contra el Cáncer (AECC; PRYCO211023SERR, funding CM). A. Vivancos is supported by the Instituto de Salud Carlos III-investigación en Salud (PI20/01112). Some pictures were created with BioRender.